Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of complement-mediated hemolytic uremic syndrome (HUS)/atypical HUS (aHUS) or thrombotic microangiopathies (TMA)
Establishing a diagnosis and, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved
Identifying variants in genes encoding complement alternate pathway components and specific coagulation pathway genes known to be associated with increased risk for aHUS/TMA allowing for predictive testing of at-risk family members
This test uses next-generation sequencing to test for variants in the ADAMTS13, C3, CD46 (MCP), CFB, CFD, CFH, CFHR1, CFHR3, CFHR5, CFI, DGKE, PLG, and THBD genes.
This test uses Sanger sequencing to test for variants in certain exons of the following genes:
PLG Exons 1, 4, and 19
CFH Exons 20-22
CFHR1 Exons 4
CFHR3 Exons 4 and 5
Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling.
This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate for the genes listed on the panel.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FIBR | Fibroblast Culture | Yes | No |
CRYOB | Cryopreserve for Biochem Studies | No | No |
For skin biopsy or cultured fibroblast specimens, fibroblast culture and cryopreservation testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.
Custom Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Supplemental Sanger Sequencing
ADAMTS13
Atypical hemolytic uremic syndrome (aHUS)
C3
CD46 (MCP)
CFB
CFD
CFH
CFHR1
CFHR3
CFHR5
CFI
Complement factor B deficiency
Complement factor D deficiency
Complement factor H deficiency
Complement factor I deficiency
DGKE
Dysplasminogenemia
Familial thrombotic thrombocytopenic purpura
Nephrotic syndrome
Plasminogen deficiency
PLG
THBD
Thrombophilia
Primary Immunodeficiency
Next Gen Sequencing Test
For skin biopsy or cultured fibroblast specimens, fibroblast culture and cryopreservation testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.
Varies
1. Primary Immunodeficiencies Patient Information (T791) is strongly recommended, but not required, to be filled out and sent with the specimen. This information aids in providing a more thorough interpretation of test results. Ordering providers are strongly encouraged to complete the form and send it with the specimen.
2. Include physician name and phone number with specimen.
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Submit only 1 of the following specimens:
Preferred:
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 14 days
Specimen Type: Blood spot
Supplies: Card-Blood Spot Collection Filter Paper (T493)
Container/Tube:
Preferred: Collection card (Whatman Protein Saver 903 Paper)
Acceptable: Whatman FTA Classic paper, Ahlstrom 226 filter paper, or Blood Spot Collection Card
Specimen Volume: 2 to 5 Blood spots on collection card
Collection Instructions:
1. An alternative blood collection option for a patient older than 1 year of age is finger stick. See Dried Blood Spot Collection Tutorial for how to collect blood spots.
2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.
3. Do not expose specimen to heat or direct sunlight.
4. Do not stack wet specimens.
5. Keep specimen dry.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Additional Information:
1. For collection instructions, see Blood Spot Collection Instructions in Special Instructions.
2. For collection instructions in Spanish, see Blood Spot Collection Card-Spanish Instructions (T777) in Special Instructions.
3. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800) in Special Instructions.Specimen Type: Peripheral blood mononuclear cells (PBMC)
Container/Tube: Cell pellet
Collection Instructions: Send as a suspension in freezing medium or cell pellet frozen on dry ice.
Specimen Stability Information: Frozen
Specimen Type: Cultured fibroblasts
Container/Tube: T-75 or T-25 flask
Specimen Volume: 1 Full T-75 or 2 full T-25 flasks
Specimen Stability Information: Ambient (preferred)/Refrigerated <24 hours
Additional Information: Indicate the tests to be performed on the fibroblast culture cells. A separate culture charge will be assessed under FIBR / Fibroblast Culture. An additional 4 weeks is required to culture fibroblasts before genetic testing can occur.
Specimen Type: Skin biopsy
Supplies: Fibroblast Biopsy Transport Media (T115)
Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin. Tubes of culture media can be supplied upon request (Eagle's minimum essential medium with 1% penicillin and streptomycin).
Specimen Volume: 4-mm punch
Specimen Stability Information: Refrigerated (preferred)/Ambient
Additional Information: A separate culture charge will be assessed under FIBR / Fibroblast Culture. An additional 4 weeks is required to culture fibroblasts before genetic testing can occur.
Specimen Type: Extracted DNA
Container/Tube: 2 mL screw top tube
Specimen Volume: 100 mcL (microliters)
Collection Instructions:
1. The preferred volume is 100 mcL at a concentration of 250 ng/mcL
2. Include concentration and volume on tube.
Specimen Stability Information: Frozen (preferred) 1 year/Ambient/Refrigerated
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Primary Immunodeficiencies Patient Information (T791) is recommended. See Special Instructions.
3. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Renal Diagnostics Test Request (T830)
-Coagulation Test Request (T753)
Whole blood: 1 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies (preferred) |
Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of complement-mediated hemolytic uremic syndrome (HUS)/atypical HUS (aHUS) or thrombotic microangiopathies (TMA)
Establishing a diagnosis and, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved
Identifying variants in genes encoding complement alternate pathway components and specific coagulation pathway genes known to be associated with increased risk for aHUS/TMA allowing for predictive testing of at-risk family members
This test uses next-generation sequencing to test for variants in the ADAMTS13, C3, CD46 (MCP), CFB, CFD, CFH, CFHR1, CFHR3, CFHR5, CFI, DGKE, PLG, and THBD genes.
This test uses Sanger sequencing to test for variants in certain exons of the following genes:
PLG Exons 1, 4, and 19
CFH Exons 20-22
CFHR1 Exons 4
CFHR3 Exons 4 and 5
Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling.
For skin biopsy or cultured fibroblast specimens, fibroblast culture and cryopreservation testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.
Complement-mediated hemolytic uremic syndrome, also known as atypical hemolytic uremic syndrome (aHUS), is a well-recognized disease entity characterized by complement activation in the microvasculature. Abnormalities of the alternate pathway of complement, which may be inherited (genetic) or acquired, underlie both the sporadic and familial forms of the disease and are identified in at least two-thirds (approximately 60%) of patients. Unlike many other monogenic disorders of the immune system, multiple hits may be required for disease manifestation, which may include a trigger event (transplantation, pregnancy, malignant hypertension, autoimmune disorders, sepsis, malignancy, etc), and 1 or more contributing genetic variants or haplotypes in the alternate pathway complement genes. The overall prognosis is poor with most patients developing end-stage kidney disease or permanent kidney injury within 1 year of diagnosis despite plasma exchange (PLEX/PEX) or plasma infusion (PI) therapy. Kidney transplantation in most patients is also associated with a poor prognosis with loss of the allograft. Drugs targeting the complement pathway, notably Eculizumab, have achieved success in modulating clinical remission and there are a few reports of combined liver-kidney transplants for these patients. Newer therapies are also likely to emerge over time. Individuals with genetic aHUS frequently experience relapse even after complete recovery following the presenting episode. Complement-mediated HUS presents with clinical features that are nearly identical to thrombotic thrombocytopenic purpura (TTP) and Shiga-toxin HUS (ST-HUS), making laboratory differentiation essential.
TTP is a rare clinical entity but is an important diagnosis as it is associated with very high mortality (90%) if untreated. Mortality can be reduced by early PLEX. Congenital TTP is due to genetic defects in the ADAMTS13 gene, while acquired TTP is related to autoantibodies against ADAMTS13, which reduces function. While TTP was initially characterized by thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurological signs, kidney failure and fever, the disease can present with only some of these features. The thrombotic microangiopathies (TMA) cover both aHUS and TTP and the clinical distinctions are not always clear-cut. Besides the thrombocytopenia, which is one of the key features of TMA, there is presence of schistocytes and highly increased levels of lactate dehydrogenase.
Complement-mediated HUS is considered genetic when 2 or more members of the same family are affected by the disease at least 6 months apart and exposure to a common triggering infectious agent has been excluded, or when pathogenic variants are identified in 1 or more of the genes known to be associated with aHUS, irrespective of familial history. A patient may have both autoantibodies to complement alternate pathway proteins and genetic defects in these genes.
It is important to note that certain genetic defects in these genes, eg, complement C3, may be associated with a more classic immunodeficiency phenotype with recurrent infections with encapsulated pathogens and connective tissue diseases with no evidence of aHUS/TMA.
Table. Genes included in this panel
Gene symbol (alias) | Protein | OMIM | Incidence | Inheritance | Phenotype disorder |
ADAMTS13 | A disintegrin and metalloproteinase with thrombospondin motifs 13 isoform 1 preproprotein | 604134 | Not available | AR | Familial thrombotic thrombocytopenic purpura |
C3 | Complement C3 preproprotein | 120700 | Approximately 5% of aHUS | AD, AR | C3 deficiency (AR), susceptibility to aHUS (AD) |
CD46 (MCP) | Membrane cofactor protein isoform 1 precursor | 120920 | Approximately 12% of aHUS | AD, AR | Susceptibility to aHUS 2 |
CFB | Complement factor B preproprotein | 138470 | Rare | AD | Complement factor B deficiency, susceptibility to aHUS 4 |
CFD | Complement factor D isoform 1 preproprotein | 134350 | Rare | AR | Complement factor D deficiency |
CFH | Complement factor H isoform a precursor | 134370 | Approximately 30% of aHUS patients | AD, AR | Complement factor H deficiency, susceptibility to aHUS 1 |
CFHR1 | Complement factor H-related protein 1 precursor | 134371 | Rare | AD, AR | Susceptibility to aHUS |
CFHR3 | Complement factor H-related protein 3 isoform 1 precursor | 605336 | Rare | AD, AR | Susceptibility to aHUS |
CFHR5 | Complement factor H-related protein 5 precursor | 608593 | 3% of aHUS | AD | Nephropathy due to CFHR5 deficiency |
CFI | Complement factor I isoform 2 preproprotein | 217030 | 4%-10% of aHUS | AD, AR | Complement factor I deficiency (AR), susceptibility to aHUS (AD) |
DGKE | Diacylglycerol kinase epsilon | 601440 | Rare | AR | Nephrotic syndrome Type 7, susceptibility to aHUS |
PLG | Plasminogen isoform 1 precursor | 173350 | Rare | AR | Dysplasminogenemia, plasminogen deficiency Type I |
THBD | Thrombomodulin precursor | 188040 | Approximately 3%-5% of aHUS | AD | Thrombophilia due to thrombomodulin defect, susceptibility to aHUS |
An interpretive report will be provided.
Evaluation and categorization of variants is performed using the most recent published American College of Medical Genetics and Genomics (ACMG) recommendations as a guideline.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and predictions made by these tools may change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.
Clinical Correlations:
Some individuals who have involvement of one or more of the genes on the panel may have a variant that is not identified by the methods performed (eg, promoter variants, deep intronic variants). The absence of a variant, therefore, does not eliminate the possibility of disease. Test results should be interpreted in context of clinical findings, family history, and other laboratory data (especially complement serological analyses). Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
Note, several genes included on this panel (C3, CFB, CFH, CFHR1, CFHR3, and CFI) have high frequency (>1%) sequence variants or haplotypes that have been identified as protective alleles or susceptibility alleles for age-related macular degeneration (ARMD). High frequency variants in these genes (>1%) are not included on this report.
For predictive testing of asymptomatic individuals, it is often useful to first test an affected family member. Identification of a pathogenic variant in an affected individual allows for more informative testing of at-risk individuals.
Technical Limitations:
Next-generation sequencing may not detect all types of genetic variants. The variant detection software has lower detection efficiency for insertion/deletion variants as compared to single nucleotide variants. Therefore, small deletions and insertions greater than 8 nucleotides in length may not be detected by this test. Copy number variations are not currently reported for any of the genes on this panel. Additionally, rare alterations (ie, polymorphisms) may be present that could lead to false-negative or false-positive results. In some cases, DNA variants of undetermined significance may be identified. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis.
If the patient has had an allogeneic blood or bone marrow transplant or a recent (ie, <6 weeks from time of sample collection) heterologous blood transfusion, results may be inaccurate due to the presence of donor DNA. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Reclassification of Variants Policy:
At this time, it is not standard practice for the laboratory to systematically review likely deleterious alterations or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time. Consultation with a healthcare provider, or team of healthcare providers, with expertise in genetics and primary immunodeficiencies, is recommended for interpretation of this result.
A list of benign and likely benign variants detected for this patient is available from the lab upon request.
Contact the laboratory if additional information is required regarding the transcript or human genome assembly used for the analysis of this patient's results.
1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424
2. Picard C, Gaspar HB, Al-Herz W, et al: International Union of Immunological Societies: 2017 Primary Immunodeficiency Disease Committee Report on inborn errors of immunity. J Clin Immunol. 2018;38:96-128
3. Noris M, Bresin E, Mele C, et al: Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Ardinger HH, Pagon RA, eds. GeneReviews [Internet]. University of Washington, Seattle; 2007. Updated June 9, 2016. Accessed July 2018. Available at www.ncbi.nlm.nih.gov/books/NBK1367/
4. Kavanagh D, Goodship THJ: Atypical hemolytic uremic syndrome, genetic basis and clinical manifestations. Hematology. (ASH); 2011:15-20
5. George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:1654-1666
6. Go RS, Winters JL, Leung N, et al: Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proceedings. 2016;91(9):1189-1211
Next-generation sequencing (NGS) is performed using an Illumina instrument with paired-end reads. The DNA is prepared for NGS using a custom Agilent SureSelect Target Enrichment System. Data is analyzed with a bioinformatics software pipeline. Supplemental Sanger sequencing is performed in select regions including CFH (exons 21-22), CFHR1 (exon 4), CFHR3 (exons 4-5) and PLG (exons 1, 4, and 19). Additional supplemental Sanger sequencing may be performed occasionally in regions where NGS is insufficient for data capture or not specific enough to correctly identify a variant.(Unpublished Mayo method)
Genes analyzed: ADAMTS13, C3, CD46 (MCP), CFB, CFD, CFH, CFHR1, CFHR3, CFHR5, CFI, DGKE, PLG, THBD.
Monday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
81479
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
AHUSP | Complement aHUS/TMA Gene Panel | In Process |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
BA3870 | Gene(s) Evaluated | 48018-6 |
BA3871 | Result Summary | 50397-9 |
BA3872 | Result Details | 82939-0 |
BA3873 | Interpretation | 69047-9 |
BA3874 | Additional Information | 48767-8 |
BA3875 | Method | 85069-3 |
BA3876 | Disclaimer | 62364-5 |
BA3877 | Reviewed by | 18771-6 |